PT  - JOURNAL ARTICLE
AU  - Melisa J. Masuda-Herrera
AU  - Joel P. Bercu
AU  - Thomas H. Broschard
AU  - Anders Burild
AU  - Catrin Hasselgren
AU  - Patricia Parris
AU  - Lucie C. Ford
AU  - Jessica Graham
AU  - Brad Stanard
AU  - Michele Comerford
AU  - Daniel Lettiere
AU  - Steffen Erler
AU  - Courtney M. Callis
AU  - Eric Morinello
AU  - Wolfgang Muster
AU  - Elizabeth A. Martin
AU  - Troy R. Griffin
AU  - Lee Nagao
AU  - Maureen Cruz
TI  - Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)
AID  - 10.5731/pdajpst.2021.012693
DP  - 2022 Sep 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - 369--383
VI  - 76
IP  - 5
4099  - http://journal.pda.org/content/76/5/369.short
4100  - http://journal.pda.org/content/76/5/369.full
SO  - PDA J Pharm Sci Technol2022 Sep 01; 76
AB  - The threshold of toxicological concern (TTC), i.e., the dose of a compound lacking sufficient experimental toxicity data that is unlikely to result in an adverse health effect in humans, is important for evaluating extractables and leachables (E&Ls) as it guides analytical testing and minimizes the use of animal studies. The Extractables and Leachables Safety Information Exchange (ELSIE) consortium, which consists of member companies that span biotechnology, pharmaceutical, and medical device industries, brought together subject matter expert toxicologists to derive TTC values for organic, non-mutagenic E&L substances when administered parenterally. A total of 488 E&L compounds from the ELSIE database were analyzed and parenteral point of departure (PPOD) estimates were derived for 252 compounds. The PPOD estimates were adjusted to extrapolate to subacute, subchronic, and chronic durations of nonclinical exposure and the lower fifth percentiles were calculated. An additional 100-fold adjustment factor to account for nonclinical species and human variability was subsequently applied to derive the parenteral TTC values for E&Ls. The resulting parenteral TTC values are 35, 110, and 180 μg/day for human exposures of >10 years to lifetime, >1-10 years, and ≤1 year, respectively. These parenteral TTCs are expected to be conservative for E&Ls that are considered non-mutagenic per ICH M7(R1) guidelines.